Effects of eribulin mesilate for tumor progression and fibrosis in gastric cancer

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter T. Kurata
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors T. Kurata1, S. Fushida1, T. Tsukada2, J. Kinoshita1, K. Oyama1, T. Ohta1
  • 1Kanazawa University Hospital, Kanazawa, Japan, /
  • 2Department of Gastroenterological Surgery, Kanazawa University Hospital, Kanazawa, Japan, /

Abstract

The prognosis of scirrhous gastric carcinoma is still very poor. Peritoneal dissemination is the most frequent metastatic pattern of scirrhous gastric carcinoma, and has extensive stromal fibrosis and invasive growth to other organs. It is known that cancer cells acquire their malignant potential from interaction with surrounding cells, including cancer-associated myofibroblasts (CAFs). Epithelial-mesenchymal transition (EMT) has an important role in the process and also seen in CAFs, which contributes to stromal fibrosis. Eribulin mesilate (Eribulin) is a non-taxane microtube dynamics inhibitor and currently approved for patients with locally-invasive or metastatic breast cancer. In addition to inhibition of tubules, recent reports have showed that eribulin prevented EMT, remodeled abnormal tumor vasculature, and had synergistic antitumor effects with other agents in triple negative breast cancer. The purpose of this study is to investigate eribulin effects for tumor progression and fibrosis in gastric cancer (GC).